Human Pheromone Sciences Inc. (EROX) Financials Nov 14, 2014, 8:10 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Human Pheromone Sciences Inc.
Fiscal year is January-December. All values USD millions. 2007 2008 2009 2010 2011 5-year trend
Sales/Revenue 1.29M 992,000 885,000 806,000 569,000
Cost of Goods Sold (COGS) incl. D&A 376,000 322,000 195,000 128,000 87,000
COGS excluding D&A 374,000 321,000 194,000 127,000 87,000
Depreciation & Amortization Expense 2,000 1,000 1,000 1,000 0
Depreciation 2,000 1,000 1,000 1,000 -
Amortization of Intangibles 0 0 0 0 -
Gross Income 915,000 670,000 690,000 678,000 482,000
2007 2008 2009 2010 2011 5-year trend
SG&A Expense 991,000 936,000 976,000 773,000 529,000
Research & Development 49,000 47,000 85,000 23,000 18,000
Other SG&A 942,000 889,000 891,000 750,000 511,000
Other Operating Expense 0 0 0 0 -
Unusual Expense 0 0 0 0 0
EBIT after Unusual Expense 0 0 0 0 0
Non Operating Income/Expense 0 0 0 0 -
Non-Operating Interest Income 65,000 30,000 3,000 - -
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense 0 0 0 0 0
Gross Interest Expense 0 0 0 0 0
Interest Capitalized 0 0 0 0 -
Pretax Income (11,000) (236,000) (283,000) (95,000) (43,000)
Income Tax 5,000 3,000 1,000 2,000 1,000
Income Tax - Current Domestic 0 0 0 0 -
Income Tax - Current Foreign 0 0 - 0 -
Income Tax - Deferred Domestic 5,000 3,000 1,000 2,000 -
Income Tax - Deferred Foreign 0 0 - 0 -
Income Tax Credits 0 0 0 0 -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 - - -
Consolidated Net Income (16,000) (239,000) (284,000) (97,000) (44,000)
Minority Interest Expense 0 0 0 0 0
Net Income (16,000) (239,000) (284,000) (97,000) (44,000)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 -
Cumulative Effect - Accounting Chg - - 0 0 -
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (16,000) (239,000) (284,000) (97,000) (44,000)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (16,000) (239,000) (284,000) (97,000) (44,000)
EPS (Basic) () (0.06) (0.07) (0.02) (0.01)
Basic Shares Outstanding 4.15M 4.15M 4.15M 4.15M 4.15M
EPS (Diluted) () (0.06) (0.07) (0.02) (0.01)
Diluted Shares Outstanding 4.15M 4.15M 4.15M 4.15M 4.15M
EBITDA (74,000) (265,000) (285,000) (94,000) (47,000)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Human Pheromone Sciences Inc.
Fiscal year is January-December. All values USD millions. 2007 2008 2009 2010 2011 5-year trend
Sales/Revenue 1.29M 992,000 885,000 806,000 569,000
Cost of Goods Sold (COGS) incl. D&A 376,000 322,000 195,000 128,000 87,000
COGS excluding D&A 374,000 321,000 194,000 127,000 87,000
Depreciation & Amortization Expense 2,000 1,000 1,000 1,000 0
Depreciation 2,000 1,000 1,000 1,000 -
Amortization of Intangibles 0 0 0 0 -
Gross Income 915,000 670,000 690,000 678,000 482,000
2007 2008 2009 2010 2011 5-year trend
SG&A Expense 991,000 936,000 976,000 773,000 529,000
Research & Development 49,000 47,000 85,000 23,000 18,000
Other SG&A 942,000 889,000 891,000 750,000 511,000
Other Operating Expense 0 0 0 0 -
Unusual Expense 0 0 0 0 0
EBIT after Unusual Expense 0 0 0 0 0
Non Operating Income/Expense 0 0 0 0 -
Non-Operating Interest Income 65,000 30,000 3,000 - -
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense 0 0 0 0 0
Gross Interest Expense 0 0 0 0 0
Interest Capitalized 0 0 0 0 -
Pretax Income (11,000) (236,000) (283,000) (95,000) (43,000)
Income Tax 5,000 3,000 1,000 2,000 1,000
Income Tax - Current Domestic 0 0 0 0 -
Income Tax - Current Foreign 0 0 - 0 -
Income Tax - Deferred Domestic 5,000 3,000 1,000 2,000 -
Income Tax - Deferred Foreign 0 0 - 0 -
Income Tax Credits 0 0 0 0 -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 - - -
Consolidated Net Income (16,000) (239,000) (284,000) (97,000) (44,000)
Minority Interest Expense 0 0 0 0 0
Net Income (16,000) (239,000) (284,000) (97,000) (44,000)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 -
Cumulative Effect - Accounting Chg - - 0 0 -
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (16,000) (239,000) (284,000) (97,000) (44,000)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (16,000) (239,000) (284,000) (97,000) (44,000)
EPS (Basic) () (0.06) (0.07) (0.02) (0.01)
Basic Shares Outstanding 4.15M 4.15M 4.15M 4.15M 4.15M
EPS (Diluted) () (0.06) (0.07) (0.02) (0.01)
Diluted Shares Outstanding 4.15M 4.15M 4.15M 4.15M 4.15M
EBITDA (74,000) (265,000) (285,000) (94,000) (47,000)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
